MedTrace Logo

Efficacy and Safety of XT-150 in Osteoarthritis of the Knee

NCT04124042 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 289

Last updated 2025-03-27

Study results available
· View outcomes & findings →

Summary

This is a Phase 2 safety and efficacy study of XT-150 in adult participants experiencing moderate to severe pain due to osteoarthritis of the knee.

Conditions

  • Osteoarthritis, Knee

Interventions

BIOLOGICAL

XT-150

plasmid DNA

DRUG

Placebo

Placebo is a sterile phosphate-buffered saline

Sponsors & Collaborators

  • Xalud Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-14
Primary Completion
2022-04-26
Completion
2022-04-26
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04124042 on ClinicalTrials.gov